Nivalis Therapeutics Inc. (NVLS) Lowered to Market Perform at Raymond James Financial Inc.
Nivalis Therapeutics Inc. (NASDAQ:NVLS) was downgraded by equities researchers at Raymond James Financial Inc. from an “outperform” rating to a “market perform” rating in a report issued on Tuesday.
Other equities research analysts also recently issued research reports about the company. Cowen and Company downgraded Nivalis Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday. Robert W. Baird downgraded Nivalis Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $29.00 to $3.00 in a report on Tuesday. Stifel Nicolaus downgraded Nivalis Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $16.00 to $3.25 in a report on Tuesday. Zacks Investment Research upgraded Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a report on Saturday, November 5th. Finally, HC Wainwright reiterated a “buy” rating on shares of Nivalis Therapeutics in a report on Monday, August 8th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $9.60.
Shares of Nivalis Therapeutics (NASDAQ:NVLS) traded down 54.24% during midday trading on Tuesday, reaching $2.86. The company’s stock had a trading volume of 1,818,249 shares. The firm has a 50-day moving average of $6.46 and a 200-day moving average of $5.84. The stock’s market cap is $44.45 million. Nivalis Therapeutics has a one year low of $2.78 and a one year high of $9.45.
Nivalis Therapeutics (NASDAQ:NVLS) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.48) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.11. On average, analysts forecast that Nivalis Therapeutics will post ($2.10) EPS for the current year.
In other Nivalis Therapeutics news, EVP David Malcom Rodman sold 5,820 shares of the company’s stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total value of $46,327.20. Following the completion of the transaction, the executive vice president now owns 18,056 shares in the company, valued at approximately $143,725.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.00% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in NVLS. Paloma Partners Management Co acquired a new position in shares of Nivalis Therapeutics during the second quarter worth about $105,000. Bank of New York Mellon Corp increased its position in shares of Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock worth $134,000 after buying an additional 1,189 shares during the period. Spark Investment Management LLC acquired a new position in shares of Nivalis Therapeutics during the third quarter worth about $145,000. Endurant Capital Management LP increased its position in shares of Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock worth $694,000 after buying an additional 19,629 shares during the period. Finally, Opaleye Management Inc. increased its position in shares of Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock worth $1,287,000 after buying an additional 160,000 shares during the period. Hedge funds and other institutional investors own 79.26% of the company’s stock.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Receive News & Stock Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related stocks with our FREE daily email newsletter.